Basketball Hall-of-Famer, Bill Walton, Tours the Nation to Speak About Life-Changing Spine Surgery

Basketball Hall-of-Famer, Bill Walton, Tours the Nation to Speak About Life-Changing Spine Surgery 
SAN DIEGO, CA -- (Marketwire) -- 02/07/13 --  NuVasive, Inc. (NASDAQ:
NUVA), a medical device company focused on developing minimally
disruptive surgical products and procedures for the spine, announced
today that Bill Walton, Basketball Hall-of-Famer and a Better Way
Back(R) patient ambassador, has successfully completed a nationwide
tour speaking about the benefits of minimally invasive spine surgery. 
For years, Bill Walton experienced debilitating chronic back and leg
pain during his years on and off the court that nearly compromised
his current position as a sports commentator. Bill's pain left him
unable to walk, sit or drive a car. After undergoing the minimally
disruptive XLIF(R) (eXtreme Lateral Interbody Fusion) procedure, Bill
found relief, has fully recovered, and is back to his active
lifestyle.  
"I was standing at the edge of the bridge, ready to jump before I
found the treatment that allowed me to play again in the wonderful
'game of life,'" said Bill Walton. "I was terrified of spine surgery
and waited too long before seeking help. With the right treatment,
doctor, and technology there is hope. As with all surgical
procedures, spine surgery carries risks that should be discussed with
a doctor, but my message to other patients is don't wait; take
control of your health and your life! If I can do it, you can too!" 
Bill is sharing his story as a key spokesman for The Better Way Back,
a patient education program developed and funded by NuVasive. The
program is dedicated to helping individuals overcome the challenges
of chronic back and leg pain by providing them with the resources
they need to find treatment and emotional support. Bill traveled
throughout Texas, North Carolina, Massachusetts and California,
speaking about his recovery to patients looking for similar solutions
to their chronic back and leg pain. Drawing on his own recovery from
debilitating back pain, Bill refers to himself as "the luckiest man
alive" and continuously provides hope and inspiration to patients and
their loved ones. 
"Since Bill has experienced debilitating back and leg pain, he has a
unique perspective in sharing his story with pre-operative patients,"
said Keith V
alentine, NuVasive President and Chief Operations
Officer. "In addition to sharing his story with pre-operative
patients as well as hospitals and clinicians, Bill acts as an
advocate for spine patients and the spine industry. Bill has
personally met with legislative and regulatory decision makers, in
hopes of improving access for spine patients to innovative treatment
options. As Bill's experience shows, thoughtful diagnosis and
treatment gives patients a new start, filled with activity and free
from pain."  
For more information about The Better Way Back or to speak to Bill
Walton about his work as a Patient Ambassador, please visit
www.thebetterwayback.org, or call 1-800-745-7099. 
About NuVasive 
NuVasive is a medical device company focused on developing minimally
disruptive surgical products and procedurally integrated solutions
for the spine. The Company is the 4th largest player in the $8.2
billion global spine market. NuVasive's principal product offering is
based on its Maximum Access Surgery, or MAS(R) platform. The MAS
platform combines several categories of solutions that collectively
minimize soft tissue disruption during spine surgery with maximum
visualization and safe, easy reproducibility for the surgeon: a
proprietary software-driven nerve avoidance system and
intra-operative monitoring support; MaXcess(R), a unique split-blade
retractor system; a wide variety of specialized implant
s; and several
biologic fusion enhancers. MAS significantly reduces surgery time and
returns patients to activities of daily living much faster than
conventional approaches. Having redefined spine surgery with the MAS
platform's lateral approach, known as eXtreme Lateral Interbody
Fusion, or XLIF(R), NuVasive has built an entire spine franchise.
With over 80 products today spanning lumbar, thoracic and cervical
applications, the Company will continue to expand and evolve its
offering predicated on its R&D focus and dedication to outstanding
service levels supported by a culture of Absolute Responsiveness(R).  
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
potential risks and uncertainties that could cause actual growth and
results to differ materially include, but are not limited to: the
risk that NuVasive's revenue or earnings projections may turn out to
be inaccurate because of the preliminary nature of the forecasts and
the risk of further adjustment, or unanticipated difficulty in
selling products or generating expected profitability; the uncertain
process of seeking regulatory approval or clearance for NuVasive's
products or devices, including risks that such process could be
significantly delayed; the possibility that the FDA may require
significant changes to NuVasive's products or clinical studies; the
risk that products may not perform as intended and may therefore not
achieve commercial success; the risk that competitors may develop
superior products or may have a greater market position enabling more
successful commercialization; the risk that additional clinical data
may call into question the benefits of NuVasive's products to
patients, hospitals and surgeons; and other risks and uncertainties
more fully described in NuVasive's press releases and periodic
filings with the Securities and Exchange Commission. NuVasive's
public filings with the Securities and Exchange Commission are
available at www.sec.gov. NuVasive assumes no obligation to update
any forward-looking statement to reflect events or circumstances
arising after the date on which it was made. 
Contact:
Investors:
Stephan Ogilvie 
VP, Corporate Development & Investor Relations 
NuVasive, Inc.
201-322-6515
investorrelations@nuvasive.com 
Media:
Nicholas S. Laudico
The Ruth Group
646-536-7030
nlaudico@theruthgroup.com 
 
 
Press spacebar to pause and continue. Press esc to stop.